Une étude conclut que les bêta-bloquants n'apportent aucun bénéfice après un infarctus sans complications

25 mai 2026

Rapporté par l'IA

Une importante étude internationale a révélé que les bêta-bloquants ne présentent aucun avantage pour les patients ayant subi un infarctus sans complications tout en conservant une fonction cardiaque normale. Les résultats de l'essai REBOOT remettent en question des décennies de pratique médicale standard. Les femmes participant à l'étude ont été confrontées à des risques plus élevés lors de la prise de ces médicaments.

L'essai REBOOT a recruté 8505 patients dans 109 hôpitaux en Espagne et en Italie. Les participants ont été répartis de manière aléatoire pour recevoir des bêta-bloquants ou ne pas en prendre après leur sortie de l'hôpital, tout en bénéficiant des soins standards modernes. Les chercheurs les ont suivis pendant une durée médiane de près de quatre ans et n'ont constaté aucune réduction significative du taux de décès, de récidives d'infarctus ou d'hospitalisations pour insuffisance cardiaque chez les personnes ayant conservé une fonction cardiaque normale.

Articles connexes

Illustration of a doctor discussing positive kidney treatment results with a patient using digital graphs.

Finerenone slows kidney decline in non-diabetic CKD trial; pooled analysis suggests broader benefits across CKD

8 juin 2026 Rapporté par l'IA Image générée par IA Vérifié par des faits

New data presented at the European Renal Association’s 63rd Congress in Glasgow and published in three major medical journals found that finerenone slowed kidney-function decline in adults with chronic kidney disease (CKD) without diabetes and reduced the risk of a combined kidney-and-cardiovascular outcome. A separate pooled analysis that combined results across finerenone studies also reported fewer kidney and heart-failure events in a broader CKD population.

Cochrane review questions benefits of anti-amyloid Alzheimer’s drugs

A major Cochrane review of 17 clinical trials involving over 20,000 participants has concluded that drugs targeting amyloid beta in the brain provide no meaningful benefits for patients with mild cognitive impairment or early Alzheimer’s. These treatments also raise the risk of brain swelling and bleeding. Researchers urge a shift to alternative pathways for future treatments.

Review finds GLP-1 drugs linked to lower risk of heart attack, stroke and death in high-risk patients

21 mai 2026 Rapporté par l'IA Vérifié par des faits

A large review of cardiovascular outcome trials found that people taking GLP-1 receptor agonists—drugs that include semaglutide (sold as Ozempic)—had a lower risk of major heart-related events than those given placebo. The analysis pooled results from 11 trials involving more than 90,000 participants, with an average follow-up of nearly three years, and reported benefits across patient subgroups including those with and without diabetes.

Santé

Single-dose zilebesiran as add-on therapy lowers systolic blood pressure in KARDIA-2 trial

Santé

Brief bursts of vigorous activity tied to lower risks across eight major disease groups, study finds

Santé

Vanderbilt study finds muscle loss with weight loss drugs and surgery

Study reveals excess cortisol in 27% of resistant hypertension patients

A large U.S. study has found that 27 percent of patients with resistant hypertension have hypercortisolism, an excess of the stress hormone cortisol. The MOMENTUM study, involving 1,086 participants across 50 centers, showed this condition is far more common than previously thought in those whose blood pressure remains high despite multiple medications. The discovery suggests screening for elevated cortisol could help explain treatment failures.

Slow breathing calms anxiety without mindfulness in mice study

8 mai 2026 Rapporté par l'IA

A new study shows that slowing breathing rates can reduce anxiety-like behaviors even without any conscious effort or belief in its effects. Researchers used mice to demonstrate that the benefits come from physiological changes rather than placebo. The findings were presented at a summit in Los Angeles earlier this month.

jeudi 28 mai 2026 16h59

Une étude conclut que les bêta-bloquants n'apportent aucun bénéfice après un infarctus sans complications

Articles connexes

Finerenone slows kidney decline in non-diabetic CKD trial; pooled analysis suggests broader benefits across CKD

Cochrane review questions benefits of anti-amyloid Alzheimer’s drugs

Review finds GLP-1 drugs linked to lower risk of heart attack, stroke and death in high-risk patients

Single-dose zilebesiran as add-on therapy lowers systolic blood pressure in KARDIA-2 trial

Brief bursts of vigorous activity tied to lower risks across eight major disease groups, study finds

Vanderbilt study finds muscle loss with weight loss drugs and surgery

Study reveals excess cortisol in 27% of resistant hypertension patients

Slow breathing calms anxiety without mindfulness in mice study

Small JAMA Psychiatry trial suggests immune-targeting drug may help some treatment-resistant depression symptoms

Gene-editing drug slashes bad cholesterol 62 percent in trial

Irregular bedtimes in midlife linked to higher heart risks

Study links common IBS drugs to higher long-term death risk

Hitting urate targets with gout-lowering therapy is linked to lower cardiovascular risk in large UK study

Evolocumab reduces heart attack risk by 31% in high-risk diabetes patients

Stroke prompts rejuvenation-like changes in undamaged brain areas

Shingles vaccine cuts heart risks nearly in half in study

Ce site utilise des cookies